HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HUM
Humana Inc.
HUM's fundamentals are mixed, but it looks expensive: trading at 43x earnings, about twice its usual 20x. Analysts expect strong earnings growth, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HUM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Stable |
HUM's revenue is currently healthy, and its profitability and balance sheet are stable, but its cash flow is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HUM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $171 | -62% |
| Fair | 20x | $205 | -54% |
| Expensive | 24x | $251 | -43% |
| Forward | 26x | $444 | — |
| Current | 43x | $444 | — |
Historical ranges are pointers, not guarantees.
HUM's PE is in its expensive range at 43x. If earnings grow as analysts expect, today's price would be 26x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HUM Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Stable | |
| Moderate | |
| Low |
HUM has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
HUM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $17.03 | +66% |
| Q3 2026 | $10.29 | -3.8% |
| Q2 2026 | $10.58 | -19% |
| Q1 2026 | $9.37 | -34% |
| Q4 2025 | $9.84 | -1.4% |
| Q3 2025 | $10.70 | -6.7% |
| Q2 2025 | $13.06 | -8% |
| Q1 2025 | $14.17 | -13% |
| Q4 2024 | $9.98 | -50% |
HUM has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over HUM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
HUM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $41.2B | +26% |
| Q2 2026 | $40.9B | +26% |
| Q1 2026 | $39.6B | +23% |
| Q4 2025 | $32.5B | +11% |
| Q3 2025 | $32.6B | +11% |
| Q2 2025 | $32.4B | +9.6% |
| Q1 2025 | $32.1B | +8.4% |
| Q4 2024 | $29.2B | +10% |
HUM's revenue has grown year over year every quarter since late 2020: $41.2B last quarter, up 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.2% | -1.1 points |
| Q2 2026 | 3.3% | -0.1 points |
| Q1 2026 | 4.4% | -1.8 points |
| Q4 2025 | -2.5% | -0.6 points |
| Q3 2025 | 1.2% | -1.3 points |
| Q2 2025 | 3.4% | -0.5 points |
| Q1 2025 | 6.3% | +2.1 points |
| Q4 2024 | -1.9% | -0.5 points |
HUM has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over HUM on cash flow, with more consistent year-over-year improvement.
HUM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2B | +142% |
| Q2 2026 | -$558M | -148% |
| Q1 2026 | $1.1B | +380% |
| Q4 2025 | -$1.9B | -$1.2B |
| Q3 2025 | $836M | -52% |
| Q2 2025 | $1.2B | +5.3% |
| Q1 2025 | $236M | -4.1% |
| Q4 2024 | -$682M | +$6.7B |
HUM still generates free cash flow, though less than at its 2022 peak: $747M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over HUM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HUM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +935K shares |
| 1 year | +0.9% | +1.1M shares |
| 3 years | -1.7% | -2.2M shares |
| 5 years | -5.7% | -7.4M shares |
| Available history | -9.6% | -12.9M shares |
HUM has 122M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2M |
| Q2 2026 | $1M |
| Q1 2026 | $107M |
| Q4 2025 | $42M |
| Q3 2025 | — |
| Q2 2025 | $100M |
| Q1 2025 | $9M |
| Q4 2024 | $49M |
HUM spent $152M buying back its own shares over the past year, down 3.8% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
HUM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.0x | Healthy |
| Q2 2026 | 2.3x | Moderate |
| Q1 2026 | 2.9x | Moderate |
| Q4 2025 | 2.4x | Moderate |
| Q3 2025 | 2.0x | Healthy |
| Q2 2025 | 2.1x | Moderate |
| Q1 2025 | 2.2x | Moderate |
| Q4 2024 | 2.8x | Moderate |
HUM's net debt is about 2.0 years of its operating earnings (EBITDA), about the same as a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HUM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.9 | Neutral |
| Stochastic | 74.1 | Neutral |
HUM's weekly RSI is 67 (neutral) and its Stochastic is 74 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HUM PE vs Healthcare Sector
| Metric | HUM | Sector median | Relative |
|---|---|---|---|
| PE | 43x | 26x | 67% above |
| PE % | 100 | 29 | 71 pts above |
HUM is trading at 43x earnings, a 67% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
HUM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $418.2 | 6.1% above |
| 20 week MA | $401.2 | 11% above |
| 50 week MA | $309.6 | 43% above |
| 100 week MA | $285.0 | 56% above |
| 200 week MA | $349.2 | 27% above |
HUM has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
HUM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $371.0 | $404.8 | +9.1% |
| 2021 | $404.8 | $460.5 | +14% |
| 2022 | $460.5 | $514.0 | +12% |
| 2023 | $514.0 | $457.8 | -11% |
| 2024 | $457.8 | $255.6 | -44% |
| 2025 | $255.6 | $258.8 | +1.2% |
| 2026 YTD | $258.8 | $443.7 | +71% |
HUM has the edge over HIMS on returns for 2026, with the stronger performance.